SCHEMBL4588929

SCHEMBL4588929

CONC(=O)c1cn(-c2ccc3c(c2)CCC3)c2nc(Nc3cccc(N4CC(C)NC(C)C4)c3)ncc2c1=O

nearest known ligand 0.73

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 20/20 0.73
INSR P06213 3/20 0.66
KIT P10721 3/20 0.66
SRC P12931 3/20 0.66
FLT3 P36888 3/20 0.66
PDGFRB P09619 2/20 0.66
NTRK1 P04629 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3525624 0.92 CSF1R (0.73) CSF1RINSRKITSRCFLT3
SCHEMBL3530244 0.92 CSF1R (0.86) CSF1RKITSRCFLT3NTRK1
SCHEMBL4587836 0.91 CSF1R (0.75) CSF1RINSRKITSRCFLT3
SCHEMBL4585175 0.89 CSF1R (0.72) CSF1RINSRKITSRCFLT3
SCHEMBL4590123 0.89 CSF1R (0.84) CSF1RINSRKITSRCFLT3
SCHEMBL3530100 0.89 CSF1R (0.70) CSF1RINSRKITSRCFLT3
SCHEMBL4573716 0.88 CSF1R (0.73) CSF1RINSRKITSRCFLT3
SCHEMBL4590270 0.87 CSF1R (0.74) CSF1RINSRKITSRCFLT3
SCHEMBL4573692 0.86 CSF1R (0.80) CSF1RINSRKITSRCFLT3
SCHEMBL4573703 0.86 CSF1R (0.72) CSF1RINSRKITSRCFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080114007-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-05-15 US claimed
WO-2008055013-A2 5-OXO-5,8 - DIHYDRO - PYRIDO - PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-05-08 WO claimed
US-20080114007-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-05-15 US disclosed
US-20080114007-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-05-15 US disclosed
US-20080114007-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-05-15 US disclosed
WO-2008055013-A2 5-OXO-5,8 - DIHYDRO - PYRIDO - PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-05-08 WO disclosed
WO-2008055013-A2 5-OXO-5,8 - DIHYDRO - PYRIDO - PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114007-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE FLT3, FES, ALK CSF1R 430/4885INSR 1526/4885KIT 363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.